Ginkgo Bioworks is set to go public through a $17.5 billion merger with a special purpose acquisition company (SPAC). The deal, which involves Arie Belldegrun, will generate $2.5 billion of gross cash proceeds to support Ginkgo’s efforts to engineer cells to enable new product development.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,